These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 23540783)

  • 1. The costs of non-muscle invasive bladder cancer.
    James AC; Gore JL
    Urol Clin North Am; 2013 May; 40(2):261-9. PubMed ID: 23540783
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The burden of bladder cancer care: direct and indirect costs.
    Mossanen M; Gore JL
    Curr Opin Urol; 2014 Sep; 24(5):487-91. PubMed ID: 24887047
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Non-muscle-invasive bladder cancer surveillance for which cystoscopy is partly replaced by microsatellite analysis of urine: a cost-effective alternative?
    de Bekker-Grob EW; van der Aa MN; Zwarthoff EC; Eijkemans MJ; van Rhijn BW; van der Kwast TH; Steyerberg EW
    BJU Int; 2009 Jul; 104(1):41-7. PubMed ID: 19500328
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of fluorescence in situ hybridization assay for surveillance of non-muscle invasive bladder cancer.
    Karnwal A; Venegas R; Shuch B; Bassett J; Rajfer J; Reznichek R
    Can J Urol; 2010 Apr; 17(2):5077-81. PubMed ID: 20398445
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Economic impact of tumor markers in bladder cancer surveillance.
    Hong YM; Loughlin KR
    Urology; 2008 Jan; 71(1):131-5. PubMed ID: 18242381
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The economic benefit of photodynamic diagnosis in non-muscle invasive bladder cancer.
    Dindyal S; Nitkunan T; Bunce CJ
    Photodiagnosis Photodyn Ther; 2008 Jun; 5(2):153-8. PubMed ID: 19356647
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improving bladder cancer patient care: a pharmacoeconomic perspective.
    Gore JL; Gilbert SM
    Expert Rev Anticancer Ther; 2013 Jun; 13(6):661-8. PubMed ID: 23773101
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prospective trial to identify optimal bladder cancer surveillance protocol: reducing costs while maximizing sensitivity.
    Kamat AM; Karam JA; Grossman HB; Kader AK; Munsell M; Dinney CP
    BJU Int; 2011 Oct; 108(7):1119-23. PubMed ID: 21426474
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The cost of bladder tumour treatment and follow-up.
    Hedelin H; Holmäng S; Wiman L
    Scand J Urol Nephrol; 2002; 36(5):344-7. PubMed ID: 12487738
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Should we screen for bladder cancer in a high-risk population?: A cost per life-year saved analysis.
    Lotan Y; Svatek RS; Sagalowsky AI
    Cancer; 2006 Sep; 107(5):982-90. PubMed ID: 16862567
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Can the burden of follow-up in low-grade noninvasive bladder cancer be reduced by photodynamic diagnosis, perioperative instillations, imaging, and urine markers?
    Gakis G; Kruck S; Stenzl A
    Curr Opin Urol; 2010 Sep; 20(5):388-92. PubMed ID: 20657287
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Urine markers for detection and surveillance of non-muscle-invasive bladder cancer.
    Tilki D; Burger M; Dalbagni G; Grossman HB; Hakenberg OW; Palou J; Reich O; Rouprêt M; Shariat SF; Zlotta AR
    Eur Urol; 2011 Sep; 60(3):484-92. PubMed ID: 21684071
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of molecular and conventional strategies for followup of superficial bladder cancer using decision analysis.
    Nam RK; Redelmeier DA; Spiess PE; Sampson HA; Fradet Y; Jewett MA
    J Urol; 2000 Mar; 163(3):752-7. PubMed ID: 10687970
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hexaminolevulinate-guided fluorescence cystoscopy in the diagnosis and follow-up of patients with non-muscle-invasive bladder cancer: review of the evidence and recommendations.
    Witjes JA; Redorta JP; Jacqmin D; Sofras F; Malmström PU; Riedl C; Jocham D; Conti G; Montorsi F; Arentsen HC; Zaak D; Mostafid AH; Babjuk M
    Eur Urol; 2010 Apr; 57(4):607-14. PubMed ID: 20116164
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimal risk-adapted surveillance strategies for NMIBC, including upper tract imaging.
    Large MC; Cohn JA; Steinberg GD
    Urol Clin North Am; 2013 May; 40(2):305-15. PubMed ID: 23540787
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The value of the UroVysion assay for surveillance of non-muscle-invasive bladder cancer.
    Gudjónsson S; Isfoss BL; Hansson K; Domanski AM; Warenholt J; Soller W; Lundberg LM; Liedberg F; Grabe M; Månsson W
    Eur Urol; 2008 Aug; 54(2):402-8. PubMed ID: 18082934
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Surgical advances in bladder cancer: at what cost?
    Johnson DC; Greene PS; Nielsen ME
    Urol Clin North Am; 2015 May; 42(2):235-52, ix. PubMed ID: 25882565
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnosis and treatment of bladder cancer: how can we improve?
    Gorin MA; Ayyathurai R; Soloway MS
    Postgrad Med; 2012 May; 124(3):28-36. PubMed ID: 22691896
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical model of lifetime cost of treating bladder cancer and associated complications.
    Avritscher EB; Cooksley CD; Grossman HB; Sabichi AL; Hamblin L; Dinney CP; Elting LS
    Urology; 2006 Sep; 68(3):549-53. PubMed ID: 16979735
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluating the cost of surveillance for non-muscle-invasive bladder cancer: an analysis based on risk categories.
    Mossanen M; Wang Y; Szymaniak J; Tan WS; Huynh MJ; Preston MA; Trinh QD; Sonpavde G; Kibel AS; Chang SL
    World J Urol; 2019 Oct; 37(10):2059-2065. PubMed ID: 30446799
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.